癌症生物學治療之技術及全球市場 是由出版商BCC Research在2010年03月所出版的。
這份英文市場調查報告書包含321 pages 價格從美金4850起跳。
本報告書針對全球的癌症治療藥物做分析，從正在使用治療的到已經上市的，或是開發後期的藥物做調查，以及市場動向、至2014年為止的5年預測，投入市場之企業檔案及特別許可分析結果之統整。
第1章 簡介
第2章 摘要
第3章 概要
- 全球之癌症市場
- 全球之腫瘤學市場
- 新興市場
- 全球之癌症生物學的藥物市場
- 影響市場之課題及動向
第4章 生物學藥物
- 所謂的癌症是
- 癌症成長原因
- 癌症治療戰略
- 一般的治療方法及問題點
- 產品區分及技術
- monoclonal抗體
- 癌症治療用疫苗
- 預防疫苗
- 成長因子 其他
第5章 開發中產品
第6章 市場數據
第7章 世界癌症統計
第8章 癌症細節
- 肺癌
- 膀胱癌
- 乳癌
- 子宮頸癌
- 結腸直腸癌
- 食道癌 其他
第9章 企業／世界之投入組織
第10章 影響癌症生物學治療市場之課題及動向
- Medicare與醫療政策
- 癌症費用
- 癌症藥劑費
- 個別化醫療
- 生物額學藥劑之價格戰略
- Pharmacogenomics
- 標的癌症治療
- 生活方式及癌症預防
- 行銷與流通動向
- Biosimilars
- 特許失效及Biosimilars
- 在印度、中國的Biogenerics藥物
- Biosimilars的門檻 其他
Abstract
THIS REPORT:
- Coverage of biological products in development, in clinical trials,
currently marketed, and late-stage-development biologic cancer products
- Analysis of market trends, citing data for 2008, estimates for 2009, and
projections, including 5-year compound annual growth rates (CAGRs), through
2014
- Discussion of drug classes with special focus on cancer treatments,
including growth hormones, erythropoietin, colony stimulating factors and
interleukin-2 drugs, interferons/interferons kinases, monoclonal antibodies,
and vaccines
- Company profiles and patent analyses.
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This BCC Research report, Biological Therapies for Cancer: Technologies and
Global Markets, provides a detailed overview and thorough analysis of the
present and future global market for cancer biotherapeutics. This report
analyzes in detail the biological cancer markets. This report includes
products in this market, and detailed analyses of markets and competitive
environments, cancer markets in newly emerging therapeutics, and biosimilars
and their impact on the market. The report includes information about
significant products, key players, issues and trends, current market status of
cancer biotherapeutics, strengths, weaknesses, opportunities and threats
facing various cancer biotherapeutics already on the market, major issues
involved in the research and development (R&D) of more effective cancer
therapeutics, and new cancer therapeutics in development and in clinical
trials.
REASONS FOR DOING THE STUDY
The rise in the number of cancer diagnosis, wider access, and affordability of
treatment regimes in developing countries will stimulate growth in the world
cancer therapies market. It is the second-leading cause of death in the U.S.
and according to the American Cancer Society (ACS), 50% of men and 30% of
women will develop some form of cancer in their lifetime. Newer
biotherapeutics have emerged in the past few years that have had a significant
impact on cancer treatment and health. The market for biological therapies in
cancer treatment will nearly double in the next 5 years and reach more than
$50 billion in the next 5 to 10 years. The demand for newer and innovative
oncology drugs will continue to grow as healthcare systems worldwide emphasize
cancer detection and treatment. This report covers the current market status
of cancer biotherapeutics, strengths, weaknesses, various cancer
biotherapeutics already on the market, major issues involved in the R&D of
more effective cancer therapeutics, and new cancer therapeutics in development
and in clinical trials
SCOPE OF REPORT
The proposed report will give an update on Biological Therapies for Cancer:
Technologies and Global Markets. It will review global markets for biologic
therapeutics for cancer and will forecast trends for use of biologics and
cancer treatment through 2014. Important biologics, market share by type of
cancer, products on the market and market share by company, statistical
information for types of cancers prevalent worldwide, with special emphasis on
the U.S. market. The report also includes current issues and trends affecting
the industry, costs, and factors influencing demand will be discussed. The
report covers, biological products in development, biological products in
clinical trials, currently marketed and late-stage development biologic cancer
products. The market and sales data in 2008 provides once again strong support
for the R&D paradigm shift to biologic treatment for cancer and within
biologic toward human monoclonal antibodies (mAbs), vaccines, and interferons
(IFNs). The following biologic drug classes will be discussed in this report
with a special focus on cancer treatment:
- mAbs
- Vaccines
- Erythropoietin (EPO)
- Colony stimulating factors (CSFs)
- Interleukins (ILs) and IFNs
The following approaches to cancer therapeutics are excluded from this report:
chemotherapy, alkylating agents, antimetabolites, cytotoxic agents, plant
derivatives, and hormone therapy corticosteroids, hormone
antagonists/antagonists aromatase inhibitors selective estrogen receptor
modulators (SERMs), radiation therapy and adjunctive therapy. Biological
therapies for treatment of other diseases will not be addressed in this report.
INTENDED AUDIENCE
This report is an exhaustive study on the worldwide biological cancer
treatment market, giving crucial statistics and analysis on the prevalence of
cancer, market structure, market size, key drug segments, important trends in
technology development, major opportunities, and market shares of key players
and drugs. This report may prove crucial for the firms or investors seeking
investments in the concerned sector. Biological therapy (sometimes called
immunotherapy, biotherapy, or biological response modifier [BRM] therapy) is a
relatively new addition to the family of cancer treatments that also includes
surgery, chemotherapy, and radiation therapy. Biological therapies use the
body' s immune system, either directly or indirectly, to fight cancer or to
lessen the side effects that may be caused by some cancer treatments.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this
report. Secondary sources include books, newspapers, trade journals, white
papers, industry portals, government agencies, trade associations, monitoring
industry news and developments, and through access to paid databases. The base
year of the report is 2008, with forecast data provided through 2014.
Historical, base year and forecast data are provided for each market segment
of this report. Growth rates are determined through a compilation of data,
including past trends, future trends, demographics, incidence, mortality,
products in R&D, and current product growth, etc.
Table of Contents
Chapter- 1: INTRODUCTION -- Complimentary 4
- CHAPTER ONE: INTRODUCTION 1
- STUDY GOALS AND OBJECTIVES 1
- REASONS FOR DOING THE STUDY 1
- SCOPE OF REPORT 1
- INTENDED AUDIENCE 2
- METHODOLOGY 3
- RELATED BCC STUDIES 3
- ANALYST CREDENTIALS 3
- BCC ONLINE SERVICES 3
- DISCLAIMER 4
Chapter-2: SUMMARY 3
- SUMMARY 5
- SUMMARY TABLE GLOBAL BIOLOGICAL TREATMENT OF CANCER: MARKET BY REGION,
THROUGH 2014 ($ MILLIONS) 6
- SUMMARY FIGURE GLOBAL BIOLOGICAL TREATMENT OF CANCER: MARKET BY REGION,
2008 - 2014 ($ MILLIONS) 7
Chapter-3: OVERVIEW 17
- GLOBAL CANCER MARKET 8
- TABLE 1 ESTIMATED GLOBAL INCIDENCE OF CANCER AND FORECAST BY REGION, 2007
- 2030 (MILLIONS) 9
- FIGURE 1 ESTIMATED GLOBAL CANCER INCIDENCE AND FORECAST BY REGION, 2008 -
2030 ($ MILLIONS) 10
- TABLE 2 ESTIMATED GLOBAL CANCER-RELATED DEATHS AND FORECAST BY REGION,
2007 - 2030 (MILLIONS) 11
- FIGURE 2 ESTIMATED GLOBAL CANCER-RELATED DEATHS AND FORECAST BY REGION,
2008 AND 2030 (MILLIONS) 11
- GLOBAL ONCOLOGY MARKET 12
- TABLE 3 GLOBAL ONCOLOGY MARKET SALES AND FORECAST BY REGION, THROUGH 2014
($ MILLIONS) 13
- FIGURE 3 GLOBAL ONCOLOGY MARKET SALES AND FORECAST BY REGION, 2008 - 2014
($ MILLIONS) 13
- GLOBAL ONCOLOGY MARKET (CONTINUED) 14
- TABLE 4 GLOBAL ONCOLOGY COMPANY SALES, THROUGH 2014 ($ MILLIONS) 15
- EMERGING MARKETS 16
- TABLE 5 ONCOLOGY MARKET IN ASIA-PACIFIC BY COUNTRY, 2006 - 2008 ($
MILLIONS) 16
- TABLE 5 (CONTINUED) 17
- FIGURE 4 ONCOLOGY MARKET IN ASIA-PACIFIC BY COUNTRY, 2006 - 2008 ($
MILLIONS) 17
- GLOBAL CANCER BIOLOGICAL THERAPEUTIC MARKET 18
- TABLE 6 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG
SALES, 2008 - 2014 ($ MILLIONS) 19
- FIGURE 5 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG
SALES, 2008 - 2014 ($ MILLIONS) 19
- TABLE 7 GLOBAL BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY DRUG
CLASS, THROUGH 2014 ($ MILLIONS) 20
- FIGURE 6 GLOBAL BIOLOGICAL TREATMENT OF CANCER: MARKET BY DRUG CLASS
FORECAST, 2008 - 2014 ($ MILLIONS) 20
- SIZE AND GROWTH OF THE CANCER BIOTHERAPEUTICS MARKET 21
- TABLE 8 GLOBAL BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY PRODUCT,
THROUGH 2014 ($ MILLIONS) 21
- Size and Growth ... (Continued) 22
- ISSUES AND TRENDS AFFECTING THE MARKET 23
- Issues and Trends ... (Continued) 24
Chapter-4: BIOTHERAPEUTICS 54
- WHAT IS CANCER? 25
- CAUSES OF CANCER GROWTH 26
- CAUSES OF CANCER GROWTH (CONTINUED) 27
- CANCER TREATMENT STRATEGIES 28
- COMMON TREATMENTS AND PROBLEMS 28
- Surgery 28
- Chemotherapy 28
- Radiation Treatment 29
- Targeted Therapy 30
- Hormone Therapy 30
- Biological Therapy of Cancer 30
- Biological Therapy of Cancer (Continued) 31
- PRODUCT SEGMENTS AND TECHNOLOGY 32
- MABS 32
- TABLE 9 MABS FOR CANCER TREATMENT 33
- mAbs (Continued) 34
- mAbs: Recent Market Activities and Trends 35
- mAbs: ...(Continued) 36
- THE FUTURE FOR CANCER MONOCLONALS 37
- TABLE 10 NEW ANTIBODY-BASED DEVELOPMENTS WITH EPCAM 38
- MONOCLONALS ON THE MARKET 39
- RITUXAN (RITUXIMAB) 39
- Rituxan (Rituximab) (Continued) 40
- TABLE 11 GLOBAL BEST-SELLING MABS FOR CANCER, 2007 - 2009 ($ MILLIONS) 41
- FIGURE 7 GLOBAL BEST-SELLING MABS FOR CANCER 2007 - 2009 ($ MILLIONS) 42
- TABLE 12 U.S. BEST-SELLING MABS FOR CANCER, 2007 - 2009 ($ MILLIONS) 42
- FIGURE 8 U.S. BEST-SELLING MABS FOR CANCER, 2007 - 2009 ($ MILLIONS) 43
- AVASTIN (BEVACIZUMAB) 43
- HERCEPTIN (TRASTUZUMAB) 44
- Herceptin (Trastuzumab) (Continued) 45
- Herceptin (Trastuzumab) (Continued) 46
- CAMPATH (ALEMTUZUMAB) 47
- ERBITUX (CETUXIMAB) 48
- Erbitux (Cetuximab) (Continued) 49
- Erbitux (Cetuximab) (Continued) 50
- MYLOTARG (GEMTUZUMAB OZOGAMICIN) 51
- VECTIBIX (PANITUMUMAB) 51
- BEXXAR 52
- ZEVALIN 53
- IFNS 54
- TABLE 13 GLOBAL IFN SALES FOR CANCER, 2007 - 2009 ($ MILLIONS) 55
- FIGURE 9 GLOBAL IFN SALES FOR CANCER, 2007 - 2009 ($ MILLIONS) 55
- TABLE 14 GLOBAL IL SALES FOR CANCER, 2007 - 2009 ($ MILLIONS) 56
- ALDESLEUKIN 56
- IFN-A 57
- IFN-α (Continued) 58
- IFN-α (Continued) 59
- VACCINES 60
- THERAPEUTIC CANCER VACCINES 60
- Therapeutic Cancer Vaccines (Continued) 61
- Therapeutic Cancer Vaccines (Continued) 62
- TABLE 15 CURRENT THERAPEUTIC VACCINE DEVELOPMENT AND POTENTIAL U.S. MARKET
($ MILLIONS) 63
- PREVENTIVE CANCER VACCINES 64
- TABLE 16 GLOBAL BEST-SELLING PREVENTIVE VACCINES FOR CERVICAL CANCER, 2007
- 2014 ($ MILLIONS) 64
- FIGURE 10 GLOBAL BEST-SELLING PREVENTIVE VACCINES FOR CERVICAL CANCER, BY
COMPANY, 2007 - 2014 ($ MILLIONS) 65
- TABLE 17 U.S. BEST-SELLING PREVENTIVE VACCINES FOR CERVICAL CANCER, BY
COMPANY, 2008 - 2014 ($ MILLIONS) 65
- FIGURE 11 U.S. BEST-SELLING PREVENTIVE VACCINES FOR CERVICAL CANCER, BY
COMPANY 2008 - 2014 ($ MILLIONS) 66
- Gardasil 66
- Gardasil (Continued) 67
- Cervarix 68
- GROWTH FACTORS 69
- TABLE 18 GLOBAL SUPPORTIVE CARE DRUGS, 2007 - 2009 ($ MILLIONS) 70
- FIGURE 12 GLOBAL SUPPORTIVE CARE DRUGS, 2007 - 2009 ($ MILLIONS) 70
- TABLE 19 U.S. SUPPORTIVE CARE DRUGS, 2007 - 2009 ($ MILLIONS) 71
- FIGURE 13 U.S. SUPPORTIVE CARE DRUGS, 2007 - 2009 ($ MILLIONS) 71
- GROWTH FACTORS (CONTINUED) 72
- ARANESP 73
- PROCRIT AND EPOGEN 74
- NEULASTA 75
- NEUPOGEN 75
- LEUKINE/SARGRAMOSTIM 76
- NEUMEGA (IL-11/OPRELVEKIN) 76
- BIOSIMILARS 77
- OTHER BIOTHERAPY/GENE THERAPY 78
Chapter-5: PRODUCTS IN DEVELOPMENT 26
- PRODUCTS IN DEVELOPMENT 79
- DRUGS/COMPANIES IN DEVELOPMENT 80
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 81
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 82
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 83
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 84
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 85
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 86
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 87
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 88
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 89
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 90
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 91
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 92
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 93
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 94
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 95
- TABLE 20 BIOLOGICAL THERAPIES FOR CANCER IN CLINICAL DEVELOPMENT 96
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 97
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 98
- DRUGS/COMPANIES IN DEVELOPMENT (CONTINUED) 99
- CLINICAL TRIALS IN ONCOLOGY 100
- TABLE 21 ONCOLOGY CLINICAL TRIALS, 2009 (NUMBER) 100
- FIGURE 14 ONCOLOGY CLINICAL TRIALS, 2009 (NUMBER) 101
- NEW APPROVALS 101
- NEW APPROVALS (CONTINUED) 102
- NEW APPROVALS (CONTINUED) 103
- TABLE 22 APPROVED BIOLOGICS FOR CANCER, 2009 104
Chapter-6: MARKET DATA 21
- MARKET SIZE AND GROWTH 105
- MARKET BY PRODUCT TYPE 105
- RITUXAN 105
- AVASTIN 105
- HERCEPTIN 106
- NEULASTA 106
- ARANESP 106
- TABLE 23 GLOBAL TOP FOUR BIOLOGIC PRODUCTS BY ESTIMATED SALES, 2014 ($
MILLIONS) 107
- ONCOLOGY MARKET 107
- TABLE 24 GLOBAL TOP CANCER BIOLOGICS AND SALES, 2007 - 2009 ($ MILLIONS)
107
- FIGURE 15 GLOBAL TOP CANCER BIOLOGICS SALES, BY DRUG CLASS, 2007 - 2009 ($
MILLIONS) 108
- MARKET BY GEOGRAPHICAL SEGMENTS 108
- MARKET BY GEOGRAPHICAL SEGMENTS (CONTINUED) 109
- MARKET BY GEOGRAPHICAL SEGMENTS (CONTINUED) 110
- U.S. MARKET 111
- TABLE 25 U.S. BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST, BY DRUG
CLASS, THROUGH 2014 ($ MILLIONS) 111
- FIGURE 16 U.S. BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY DRUG
CLASS, 2009 AND 2014 ($ MILLIONS) 111
- TABLE 26 U.S. BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY PRODUCT,
THROUGH 2014 ($ MILLIONS) 112
- FIGURE 17 U.S. BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY BRAND
NAME, 2009 AND 2014 ($ MILLIONS) 112
- TABLE 27 CAMPATH SALES, 2007 AND 2008 ($ MILLIONS) 113
- JAPAN (ASIA) MARKET 113
- TABLE 28 JAPANESE BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY DRUG
CLASS, THROUGH 2014 ($ MILLIONS) 114
- FIGURE 18 JAPANESE BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY DRUG
CLASS, 2009 AND 2014 ($ MILLIONS) 114
- TABLE 29 JAPANESE BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY
PRODUCT, THROUGH 2014 ($ MILLIONS) 115
- FIGURE 19 JAPANESE BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY
BRAND, 2009 AND 2014 ($ MILLIONS) 115
- CANCER MARKET AND EUROPE 116
- EUROPEAN/ROW MARKET 117
- TABLE 30 EUROPEAN/ROW BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY
DRUG CLASS, THROUGH 2014 ($ MILLIONS) 117
- FIGURE 20 EUROPEAN/ROW BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY
DRUG CLASS, 2009 AND 2014 ($ MILLIONS) 117
- TABLE 31 EUROPEAN/ROW BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY
PRODUCT, THROUGH 2014 ($ MILLIONS) 118
- FIGURE 21 EUROPEAN/ROW BIOLOGICAL TREATMENT OF CANCER: MARKET FORECAST BY
BRAND, 2009 AND 2014 ($ MILLIONS) 118
- CANCER MARKET AND ASIA 119
- CANCER MARKET AND AUSTRALIA 119
- CANCER MARKET AND SOUTH KOREA 120
- CANCER MARKET AND CHINA 120
- CANCER MARKET AND TAIWAN 121
- CANCER MARKET AND SINGAPORE 121
- CANCER MARKET AND INDIA 122
- BIOMAB-EGFR 122
- TABLE 32 COMPANIES IN ONCOLOGY IN THE ASIA-PACIFIC REGION 122
- TABLE 32 (CONTINUED) 123
- MARKET DATA BY TOP-SELLING BIOLOGIC DRUGS 123
- TABLE 33 GLOBAL TOP-SELLING BIOLOGIC DRUGS, 2007 - 2009 ($ MILLIONS) 123
- TABLE 33 (CONTINUED) 124
- FIGURE 22 GLOBAL TOP-SELLING BIOLOGIC DRUGS, BY BRAND, 2007 - 2009 ($
MILLIONS) 124
- TABLE 34 U.S. TOP-SELLING BIOLOGIC DRUGS, 2007 - 2009 ($ MILLIONS) 125
- FIGURE 23 U.S. TOP-SELLING BIOLOGIC DRUGS, BY BRAND, 2007 - 2009 ($
MILLIONS) 125
Chapter-7: GLOBAL CANCER STATISTICS 28
- CANCER TRENDS 126
- CANCER TRENDS (CONTINUED) 127
- CANCER TRENDS (CONTINUED) 128
- TABLE 35 PROJECTED CANCER INCIDENCE WORLDWIDE, 2008 - 2030 (MILLIONS) 129
- FIGURE 24 PROJECTED CANCER INCIDENCE WORLDWIDE, 2008 - 2030 (MILLIONS) 129
- TABLE 36 GLOBAL DISTRIBUTION OF NEW CANCER CASES BY GEOGRAPHIC REGION,
2009 (MILLIONS) 130
- FIGURE 25 GLOBAL DISTRIBUTION OF NEW CANCER CASES BY GEOGRAPHIC REGION,
2009 (MILLIONS) 131
- GLOBAL CANCER INCIDENCE BY DIFFERENT TYPES OF CANCER 131
- TABLE 37 GLOBAL CANCER INCIDENCE BY CANCER TYPE, 2008 (MILLIONS) 132
- TABLE 37 (CONTINUED) 133
- FIGURE 26 GLOBAL CANCER INCIDENCE BY CANCER TYPE, 2008 (MILLIONS) 133
- TABLE 38 GLOBAL CANCER DEATHS BY CANCER TYPE, 2008 (MILLIONS) 134
- FIGURE 27 GLOBAL CANCER DEATHS BY CANCER TYPE, 2008 (MILLIONS) 135
- GLOBAL CANCER INCIDENCE BY ... (CONTINUED) 136
- TABLE 39 GLOBAL DISTRIBUTION OF CANCERS BY SITE, 2009 (MILLIONS) 137
- TABLE 40 GLOBAL NUMBER OF NEW CANCER CASES BY SITE AND GEOGRAPHIC REGION,
2009 (MILLIONS) 138
- TABLE 41 NUMBER OF NEW CANCER CASES BY SITE, 2020 (MILLIONS/%) 139
- TABLE 42 GLOBAL NUMBER OF ESTIMATED NEW CANCER CASES BY SITE AND
GEOGRAPHIC REGION, 2020 (MILLIONS) 140
- CANCER' S ECONOMIC BURDEN 141
- TABLE 43 GLOBAL CANCER: INCIDENCE AND DEATHS BY SEX, 2008 (MILLIONS) 142
- FIGURE 28 GLOBAL CANCER: INCIDENCE AND DEATHS BY SEX, 2008 (MILLIONS) 142
- EMERGING MARKETS 143
- TABLE 44 GLOBAL BIOLOGICAL TREATMENT OF CANCER: MARKET BY CANCER INCIDENCE
AND TYPE, 2007 AND 2008 (MILLIONS) 143
- TABLE 44 (CONTINUED) 144
- FIGURE 29 GLOBAL BIOLOGICAL TREATMENT OF CANCER: MARKET BY CANCER
INCIDENCE AND TYPE, 2007 AND 2008 (MILLIONS) 144
- EMERGING MARKETS (CONTINUED) 145
- AFRICA 146
- AFRICA (CONTINUED) 147
- ASIA 148
- CHINA 148
- MALAYSIA 149
- INDIA 149
- India (Continued) 150
- EUROPE 151
- NORTH AMERICA 151
- TABLE 45 U.S. CANCER INCIDENCE BY CANCER TYPE, 2007 - 2009 (MILLIONS) 152
- FIGURE 30 U.S. CANCER INCIDENCE BY CANCER TYPE, 2007 - 2009 (MILLIONS) 152
- TABLE 46 U.S. CANCER DEATHS BY CANCER TYPE, 2007 - 2009 (MILLIONS) 153
- FIGURE 31 U.S. CANCER DEATHS BY CANCER TYPE, 2007 - 2009 (MILLIONS) 153
Chapter-8: DESCRIPTION OF CANCERS 89
- LUNG CANCER 154
- LUNG CANCER (CONTINUED) 155
- LUNG CANCER TREATMENT 156
- USE OF BIOLOGICS 157
- Use of Biologics (Continued) 158
- BLADDER CANCER 159
- BLADDER CANCER (CONTINUED) 160
- BREAST CANCER 161
- BREAST CANCER (CONTINUED) 162
- BREAST CANCER (CONTINUED) 163
- HER2 EXPRESSION 164
- HER2 Expression (Continued) 165
- HER2 Expression (Continued) 166
- HER2 Expression (Continued) 167
- ANTIANGIOGENIC/HER2 AGENTS 168
- Antiangiogenic/HER2 Agents (Continued) 169
- CERVICAL CANCER 170
- VACCINES 171
- COLERECTAL CANCER (CRC) 172
- COLERECTAL CANCER (CRC) (CONTINUED) 173
- COLERECTAL CANCER (CRC) (CONTINUED) 174
- COLERECTAL CANCER (CRC) (CONTINUED) 175
- COLERECTAL CANCER (CRC) (CONTINUED) 176
- SMALL INTESTINE CANCER 177
- SMALL INTESTINE CANCER (CONTINUED) 178
- SMALL INTESTINE CANCER (CONTINUED) 179
- ESOPHAGEAL CANCER 180
- ESOPHAGEAL CANCER (CONTINUED) 181
- KIDNEY 182
- KIDNEY (CONTINUED) 183
- KIDNEY (CONTINUED) 184
- KIDNEY (CONTINUED) 185
- KIDNEY (CONTINUED) 186
- LEUKEMIA 187
- LIVER 188
- LIVER (CONTINUED) 189
- LIVER (CONTINUED) 190
- LIVER (CONTINUED) 191
- LYMPHOMA 192
- LYMPHOMA (CONTINUED) 193
- NHL 194
- NHL (Continued) 195
- TABLE 47 MABS FOR TREATMENT OF NHL 196
- NHL (Continued) 197
- MALT LYMPHOMA 198
- MANTLE CELL LYMPHOMA 199
- MEDIASTINAL B-CELL LYMPHOMA 199
- BURKITT LYMPHOMA 200
- MELANOMA 200
- MELANOMA (CONTINUED) 201
- MELANOMA (CONTINUED) 202
- MELANOMA (CONTINUED) 203
- MELANOMA (CONTINUED) 204
- MELANOMA (CONTINUED) 205
- MELANOMA (CONTINUED) 206
- MULTIPLE MYELOMA 207
- MULTIPLE MYELOMA (CONTINUED) 208
- MULTIPLE MYELOMA (CONTINUED) 209
- MULTIPLE MYELOMA (CONTINUED) 210
- BRAIN CANCER 211
- BRAIN CANCER (CONTINUED) 212
- BRAIN CANCER (CONTINUED) 213
- BRAIN CANCER (CONTINUED) 214
- GLIOMAS 215
- Astrocytomas 215
- Astrocytomas (Continued) 216
- Oligodendroglioma 217
- Ependymoma 217
- MENINGIOMAS 217
- ACOUSTIC NEUROMA/SCHWANNOMAS 218
- MEDULLOBLASTOMA 218
- OVARIAN CANCER 219
- OVARIAN CANCER (CONTINUED) 220
- Epithelial Tumors 221
- Metastatic Tumors 221
- Metastatic Tumors (Continued) 222
- PANCREATIC CANCER 223
- PANCREATIC CANCER (CONTINUED) 224
- PANCREATIC CANCER (CONTINUED) 225
- PANCREATIC CANCER (CONTINUED) 226
- PANCREATIC CANCER (CONTINUED) 227
- PROSTATE CANCER 228
- PROSTATE CANCER (CONTINUED) 229
- PROSTATE CANCER (CONTINUED) 230
- PROSTATE CANCER (CONTINUED) 231
- PROSTATE CANCER (CONTINUED) 232
- PROSTATE CANCER (CONTINUED) 233
- STOMACH CANCER 234
- STOMACH CANCER (CONTINUED) 235
- STOMACH CANCER (CONTINUED) 236
- TYPES OF STOMACH CANCER 237
- Types of Stomach Cancer (Continued) 238
- Types of Stomach Cancer (Continued) 239
- CLINICAL TRIALS 240
- Phase III of Cisplatin/Fluoropyrimidine versus Cisplatin,
Fluoropyrimidine, Trastuzumab: ToGA Trial (ClinicalTrials.gov Identifier:
NCT01041404) 240
- HEAD AND NECK CANCER 240
- HEAD AND NECK CANCER (CONTINUED) 241
- HEAD AND NECK CANCER (CONTINUED) 242
Chapter-9: COMPANIES/GLOBAL PLAYERS 20
- BIOLOGICS AND COMPANIES 243
- TABLE 48 GLOBAL PRESCRIPTION SALES FOR BIOLOGIC DRUGS, THROUGH 2014 ($
MILLIONS) 243
- TABLE 49 SELECTED LEADING BIOTECH COMPANIES BY PIPELINE SIZE, 2008 (%) 244
- TABLE 50 LEADING PHARMA COMPANIES BY PIPELINE SIZE, 2008 (%) 245
- SELECTED COMPANIES AND PROFILES 246
- AMGEN 246
- GENZYME CORP. 247
- Genzyme Corp. (Continued) 248
- Oncology Drugs 249
- GLAXOSMITHKLINE 250
- JOHNSON & JOHNSON 251
- MERCK & CO. 251
- NOVARTIS 252
- Novartis (Continued) 253
- PFIZER, INC. 254
- ROCHE/GENENTECH 255
- F. Hoffmann-La Roche AG 255
- Genentech, Inc. 255
- Genentech, Inc. (Continued) 256
- Future Outlook 257
- Future Outlook (Continued) 258
- Future Outlook (Continued) 259
- Future Outlook (Continued) 260
- SCHERING-PLOUGH 261
- Schering-Plough (Continued) 262
Chapter-10: ISSUES AND TRENDS AFFECTING THE BIOLOGIC CANCER MARKET 59
- MEDICARE AND HEALTHCARE POLICIES 263
- MEDICARE AND HEALTHCARE ... (CONTINUED) 264
- CANCER COST 265
- CANCER COST (CONTINUED) 266
- CANCER DRUG COSTS 267
- CANCER DRUG COSTS (CONTINUED) 268
- CANCER DRUG COSTS (CONTINUED) 269
- PERSONALIZED MEDICINE 270
- PRICING STRATEGIES FOR CANCER BIOLOGICS 271
- PRICING STRATEGIES FOR ... (CONTINUED) 272
- PERSONALIZED MEDICINE: USING PHARMACOGENOMICS 273
- PERSONALIZED MEDICINE: ... (CONTINUED) 274
- PERSONALIZED MEDICINE: ... (CONTINUED) 275
- PERSONALIZED MEDICINE: ... (CONTINUED) 276
- PERSONALIZED MEDICINE: ... (CONTINUED) 277
- PHARMACOGENOMICS 278
- PHARMACOGENOMICS (CONTINUED) 279
- TARGETED CANCER THERAPY 280
- TARGETED CANCER THERAPY (CONTINUED) 281
- LIFESTYLES AND CANCER PREVENTION 282
- MARKETING AND DISTRIBUTION TRENDS 283
- GLOBAL TRENDS 284
- GLOBAL TRENDS (CONTINUED) 285
- GLOBAL TRENDS (CONTINUED) 286
- BIOSIMILARS 287
- PATENT EXPIRIES AND BIOSIMILARS 288
- TABLE 51 FDA APPROVAL AND PATENT EXPIRY DATES FOR MAJOR BIOPHARMACEUTICALS
($ MILLIONS) 289
- PATENT EXPIRIES AND BIOSIMILARS (CONTINUED) 290
- BIOSIMILARS AND COST OF CANCER DRUGS 291
- BIOSIMILARS AND COST OF ... (CONTINUED) 292
- BIOGENERICS, BIOSIMILARS, AND FOBS 293
- BIOSIMILAR MANUFACTURERS 294
- Biosimilar Manufacturers (Continued) 295
- BIOGENERICS IN INDIA AND CHINA 296
- Biogenerics in India and China (Continued) 297
- Biogenerics in India and China (Continued) 298
- HURDLES FOR BIOSIMILARS 299
- Hurdles for Biosimilars (Continued) 300
- DATA EXCLUSIVITY PERIODS 301
- Data Exclusivity Periods (Continued) 302
- DIFFERENCES BETWEEN BIOPHARMACEUTICALS AND BIOGENERICS 303
- Differences Between ... (Continued) 304
- Differences Between ... (Continued) 305
- Differences Between ... (Continued) 306
- Differences Between ... (Continued) 307
- BIOSIMILARS IN EUROPE 308
- Biosimilars in Europe (Continued) 309
- ISSUES WITH BIOSIMILARS 310
- ESAS BIOSIMILARS 311
- BIOSIMILARS AND PATIENT SAFETY 312
- CURRENT BIOSIMILARS 313
- Current Biosimilars (Continued) 314
- Current Biosimilars (Continued) 315
- SUMMARY 316
- CONCLUSIONS 317
- VENTURE CAPITAL AND RESEARCH INVESTMENT 318
- FUNDING CANCER RESEARCH 319
- TABLE 52 GLOBAL INVESTMENT IN CANCER RESEARCH, 2009 ($ MILLIONS) 319
- CONCLUSION 320
- BIBLIOGRAPHY 321
|
